These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8216503)

  • 1. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover.
    Seed M; O'Connor B; Perombelon N; O'Donnell M; Reaveley D; Knight BL
    Atherosclerosis; 1993 Jun; 101(1):61-8. PubMed ID: 8216503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
    O'Kane MJ; Trinick TR; Tynan MB; Trimble ER; Nicholls DP
    Br J Clin Pharmacol; 1992 Apr; 33(4):451-3. PubMed ID: 1576071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
    Sposito AC; Mansur AP; Maranhão RC; Rodrigues-Sobrinho CR; Coelho OR; Ramires JA
    Braz J Med Biol Res; 2001 Feb; 34(2):177-82. PubMed ID: 11175492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.
    Crouse JR
    Coron Artery Dis; 1996 Apr; 7(4):321-6. PubMed ID: 8853585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy.
    Tuteja S; Wang L; Dunbar RL; Chen J; DerOhannessian S; Marcovina SM; Elam M; Lader E; Rader DJ
    Pharmacogenet Genomics; 2017 Aug; 27(8):285-293. PubMed ID: 28628560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype.
    Cenarro A; Puzo J; Ferrando J; Mateo-Gallego R; Bea AM; Calmarza P; Jarauta E; Civeira F
    Metabolism; 2014 Mar; 63(3):365-71. PubMed ID: 24333007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein (a) concentrations in patients with various dyslipidaemias.
    Elisaf MS; Bairaktari ET; Tzallas CS; Siamopoulos KC
    Ann Med; 1997 Aug; 29(4):305-9. PubMed ID: 9375987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels.
    Tanaka K; Hayashi K; Shingu T; Kuga Y; Okura Y; Yasunobu Y; Ohtani H; Nomura S; Kurushima H; Saeki M; Kambe M; Kajiyama G
    Metabolism; 1997 Apr; 46(4):355-8. PubMed ID: 9109834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What restricts the clinical use of nicotinic acid?
    Kei A; Liberopoulos EN; Elisaf MS
    Curr Vasc Pharmacol; 2011 Jul; 9(4):521-30. PubMed ID: 21314634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia.
    Otto C; Parhofer KG; Ritter MM; Richter WO; Schwandt P
    Br J Clin Pharmacol; 1998 Nov; 46(5):473-8. PubMed ID: 9833601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia.
    Dean JD; McCarthy S; Betteridge DJ; Whately-Smith C; Powell J; Owens DR
    Diabet Med; 1992; 9(7):611-5. PubMed ID: 1511566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population.
    Werba JP; Safa O; Gianfranceschi G; Michelagnoli S; Sirtori CR; Franceschini G
    Atherosclerosis; 1993 Jul; 101(2):203-11. PubMed ID: 8379965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical management of dyslipidemia with elevated lipoprotein(a).
    Riche DM; East HE; Priest HM
    J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients.
    Worm D; Vinten J; Vaag A; Henriksen JE; Beck-Nielsen H
    Eur J Endocrinol; 2000 Sep; 143(3):389-95. PubMed ID: 11022182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation.
    Dursunoğlu D; Evrengül H; Polat B; Tanriverdi H; Cobankara V; Kaftan A; Kiliç M
    Rheumatol Int; 2005 May; 25(4):241-5. PubMed ID: 15290086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prolonged treatment with slow release nicotinic acid in patients with type II hyperlipidemia].
    Chojnowska-Jezierska J; Adamska-Dyniewska H
    Pol Arch Med Wewn; 1997 Nov; 98(11):391-9. PubMed ID: 9594556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
    Series JJ; Gaw A; Kilday C; Bedford DK; Lorimer AR; Packard CJ; Shepherd J
    Br J Clin Pharmacol; 1990 Jul; 30(1):49-54. PubMed ID: 2390432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein (a) in patients with hyperlipidaemia.
    Bartens W; Rader DJ; Talley G; Brewer HB
    Eur J Clin Invest; 1995 Sep; 25(9):647-53. PubMed ID: 7498237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.